Tango Therapeutics (TNGX) Guggenheim Securities Emerging Outlook: Biotech Summit 2026 summary

Leadership transition and strategic vision

• New CEO with long-standing board experience emphasizes continuity in strategy and priorities.

• Focus remains on advancing vopimetostat toward regulatory approval, leveraging recent clinical proof of concept.

• No drastic strategic changes expected following the leadership transition.

• Leadership transition was a planned and collaborative process with the previous CEO and board.

Clinical development and trial updates

• Pivotal trial protocol for vopimetostat in second-line pancreatic cancer developed, with strong FDA support and launch planned this year.

• Ongoing 300-patient monotherapy study uses a hierarchical design focusing on PFS and overall survival, with rapid enrollment anticipated.

• Combination trial with RAS inhibitors (daraxonrasib, zoldonrasib) recently started, showing early clinical activity and high enrollment interest.

• Global trial design aims to mitigate regional changes in treatment paradigms and support robust recruitment.

• Monotherapy data update and combination data are expected later this year.

Combination strategies and future opportunities

• Preclinical synergy between vopimetostat and RAS inhibitors prompted rapid clinical development; 14 patients enrolled in daraxonrasib arm, 16 in zoldonrasib arm.

• Selection of RP2D will be based on surpassing RAS inhibitor monotherapy benchmarks in second-line pancreatic cancer.

• Duration of response and PFS are key factors in decision-making for combination regimens.

• Plans to present combination study data this year, with next steps tied to data maturity and potential regulatory discussions.

• No significant efficacy difference expected between the two RAS inhibitors; future strategy will depend on emerging data.